Company News
UroGen Pharma Top SMIDCAP Pick, $2B Sales
TD Cowen selects UroGen Pharma Ltd as its leading SMIDCAP investment for 2026, highlighting its under‑appreciated Zusduri therapy.
Analysts expect 30‑40% peak market penetration for Zusduri, implying
